REDDY MEDICAL COMMUNICATIONS
rVIIa
Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

rVIIa

Recombinant factor VIIa (rFVIIa) is approved for use in controlling bleeding episodes in people with hemophilia who have developed inhibitors to replacement therapy. Due to its short half-life (t½), frequent injections are required, limiting its use as a prophylactic treatment
Click here to email us with your Comments and suggestions. This info is valuable to us in determining which animations will be on display at this site.